BioPharmX To Present At 27th Annual Roth Capital Partners Conference On March 11, 2015

MENLO PARK, Calif., March 3, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the 27^th Annual Roth Capital Partners Conference on Wednesday, March 11 at 9:00 a.m. PDT at the Ritz-Carlton, Laguna Niguel in Dana Point, California.  

Mr. Pekarsky will provide an overview of BioPharmX's business strategy as it pursues bringing novel products to market, including the company's recent commercial launch of Violet^TM iodine, a new, once-daily pill for relief of premenstrual breast discomfort.  At launch, Violet iodine was immediately available at Walgreen Co.'s drugstore.com web store and BioPharmX anticipates executing additional distribution agreements for Violet iodine with other large retail chains.

A live and archived webcast of the presentation will be available on the Investors page of the BioPharmX website at http://biopharmx.investorroom.com/.

About Violet Iodine 

Violet iodine is a daily iodine supplement for the relief of the most common symptoms of cyclic mastalgia and fibrocystic breast condition (FBC), including monthly swelling, tenderness, aches and heaviness. Violet iodine is available for sale at select CVS pharmacies and online at drugstore.com, a Walgreens web store. To learn more about Violet iodine, visit www.VioletDaily.com.

About BioPharmX Corporation

BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the fast-growing health and wellness markets, including women's health, dermatology, and otolaryngology (ears, nose & throat).  To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements

Statements in this news release relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements."  These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements.  All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company's filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risk that the commercial launch of Violet iodine is unsuccessful and that the company is unable to offer Violet iodine through other retail chains. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX and Violet are pending trademarks of BioPharmX Inc.  All other brand and product names are trademarks or registered trademarks of their respective holders.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-corporation-to-present-at-27th-annual-roth-capital-partners-conference-on-march-11-2015-300044694.html

SOURCE BioPharmX Corporation